UNLABELLED: People with both HIV and hepatitis C are more likely than those with HIV alone to have wrist, hip, and spine fractures. We compared hip strength between HIV/HCV-co-infected men and healthy men and found that HIV/HCV-co-infected men had decreased hip strength due to lower lean body mass. INTRODUCTION: Hepatitis C co-infection is a risk factor for fragility fracture among HIV-infected populations. Whether bone strength is compromised in HIV/HCV-co-infected patients is unknown. METHODS: We compared dual-energy x-ray absorptiometry (DXA)-derived hip geometry, a measure of bone strength, in 88 HIV/HCV-co-infected men from the Johns Hopkins HIV Clinic to 289 men of similar age and race and without HIV or HCV from the Boston Area Community Health Survey/Bone Survey. Hip geometry was assessed at the narrow neck, intertrochanter, and shaft using hip structural analysis. Lean body mass (LBM), total fat mass (FM), and fat mass ratio (FMR) were measured by whole-body DXA. Linear regression was used to identify body composition parameters that accounted for differences in bone strength between cohorts. RESULTS: HIV/HCV-co-infected men had lower BMI, LBM, and FM and higher FMR compared to controls (all p < 0.05). At the narrow neck, significant differences were observed between HIV/HCV-co-infected men and controls in bone mineral density, cross-sectional area, section modulus, buckling ratio, and centroid position. After adjustment for race, age, smoking status, height, and weight, only buckling ratio and centroid position remained significantly different between cohorts (all p < 0.05). Substituting LBM, FM, and FMR for weight in the multivariate model revealed that differences in LBM, but not FM or FMR, accounted for differences in all narrow neck parameters between cohorts, except buckling ratio and centroid position. CONCLUSION: HIV/HCV-co-infected men have compromised hip strength at the narrow neck compared to uninfected controls, which is attributable in large part to lower lean body mass.
UNLABELLED: People with both HIV and hepatitis C are more likely than those with HIV alone to have wrist, hip, and spine fractures. We compared hip strength between HIV/HCV-co-infectedmen and healthy men and found that HIV/HCV-co-infectedmen had decreased hip strength due to lower lean body mass. INTRODUCTION:Hepatitis C co-infection is a risk factor for fragility fracture among HIV-infected populations. Whether bone strength is compromised in HIV/HCV-co-infectedpatients is unknown. METHODS: We compared dual-energy x-ray absorptiometry (DXA)-derived hip geometry, a measure of bone strength, in 88 HIV/HCV-co-infectedmen from the Johns Hopkins HIV Clinic to 289 men of similar age and race and without HIV or HCV from the Boston Area Community Health Survey/Bone Survey. Hip geometry was assessed at the narrow neck, intertrochanter, and shaft using hip structural analysis. Lean body mass (LBM), total fat mass (FM), and fat mass ratio (FMR) were measured by whole-body DXA. Linear regression was used to identify body composition parameters that accounted for differences in bone strength between cohorts. RESULTS:HIV/HCV-co-infectedmen had lower BMI, LBM, and FM and higher FMR compared to controls (all p < 0.05). At the narrow neck, significant differences were observed between HIV/HCV-co-infectedmen and controls in bone mineral density, cross-sectional area, section modulus, buckling ratio, and centroid position. After adjustment for race, age, smoking status, height, and weight, only buckling ratio and centroid position remained significantly different between cohorts (all p < 0.05). Substituting LBM, FM, and FMR for weight in the multivariate model revealed that differences in LBM, but not FM or FMR, accounted for differences in all narrow neck parameters between cohorts, except buckling ratio and centroid position. CONCLUSION:HIV/HCV-co-infectedmen have compromised hip strength at the narrow neck compared to uninfected controls, which is attributable in large part to lower lean body mass.
Authors: C M Shikuma; R Zackin; F Sattler; D Mildvan; P Nyangweso; B Alston; S Evans; K Mulligan Journal: Clin Infect Dis Date: 2004-09-27 Impact factor: 9.079
Authors: Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Todd T Brown; Mary D Ruppe; Rory Kassner; Princy Kumar; Theresa Kehoe; Adrian S Dobs; Joseph Timpone Journal: J Clin Endocrinol Metab Date: 2004-03 Impact factor: 5.958
Authors: Wojciech P Olszynski; K Shawn Davison; Jonathan D Adachi; Jacques P Brown; Steven R Cummings; David A Hanley; Steven P Harris; Anthony B Hodsman; David Kendler; Michael R McClung; Paul D Miller; Chui Kin Yuen Journal: Clin Ther Date: 2004-01 Impact factor: 3.393
Authors: Vincent Lo Re; Kenneth Lynn; Emily R Stumm; Jin Long; Melissa S Nezamzadeh; Joshua F Baker; Andrew N Hoofnagle; Angela J Kapalko; Karam Mounzer; Babette S Zemel; Pablo Tebas; Jay R Kostman; Mary B Leonard Journal: J Infect Dis Date: 2015-03-09 Impact factor: 5.226
Authors: M T Yin; A RoyChoudhury; K Nishiyama; T Lang; J Shah; S Olender; D C Ferris; C Zeana; A Sharma; B Zingman; M Bucovsky; I Colon; E Shane Journal: Osteoporos Int Date: 2018-02-01 Impact factor: 4.507
Authors: Hila Haskelberg; Nicholas Pocock; Janaki Amin; Peter Robert Ebeling; Sean Emery; Andrew Carr; Anthony Allworth Journal: PLoS One Date: 2014-04-10 Impact factor: 3.240